U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164300) titled 'Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery' on Aug. 07.
Brief Summary: Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of tranexamic acid that should be administered. The purpose of this study is to compare different dosages of tranexamic acid in cardiac surgery using cardiopulmonary bypass regarding the duration of inhibition of fibrinolysis as measured by the ClotPro test.
Blood samples will be taken from the arterial line placed in the patient at specified time point...